Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.

Isomorphic Labs is the secretive AI life science startup spun out of Google DeepMind with the goal of solving all disease ...

aiming to 'reimagine' the entire drug discovery process Isomorphic Labs, a subsidiary of Google parent Alphabet that uses artificial intelligence (AI) for drug discovery, announced on March 31 ...

with participation from GV and existing investor Alphabet, Google’s parent, it said. The funding will accelerate further development of Isomorphic’s AI drug design engine and support ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet, raising $600 million to advance its ...